Leaderboards/Colorectal Cancer Treatments and Studies

Colorectal Cancer Treatments and Studies

Last updated July 15, 2026

Rising Stars

Fresh ink, massive impact

Researchers

1
Michelli F. Oliveira
10X Genomics (United States)
2
Marcos Díaz‐Gay
University of California San Diego
3
Erica C. Nakajima
AstraZeneca (Netherlands)
4
Fadl A. Zeineddine
Methodist Hospital
5
P.G.M. de Gooyer
The Netherlands Cancer Institute
6
Wenwei Yang
Chinese Academy of Medical Sciences & Peking Union Medical College
7
Pei-Chen Tsai
Harvard University
8
Marco Maria Germani
University of Pisa
9
Mirjam de With
Erasmus MC Cancer Institute
10
A. Vogel
Princess Margaret Cancer Centre

Papers

1
High-definition spatial transcriptomic profiling of immune cell populations in colorectal cancer
Nature Genetics|2025
191 cit.
2
Geographic and age variations in mutational processes in colorectal cancer
Nature|2025
123 cit.
3
Neoadjuvant nivolumab and relatlimab in locally advanced MMR-deficient colon cancer: a phase 2 trial
Nature Medicine|2024
102 cit.
4
Publication in ESMO Open (2024) [70 citations, W4405475772]
ESMO Open|2024
70 cit.
5
The mutagenic forces shaping the genomes of lung cancer in never smokers
Nature|2025
37 cit.
6
Treatment of patients with BRAF-mutated metastatic colorectal cancer after progression to encorafenib and cetuximab: data from a real-world nationwide dataset
ESMO Open|2024
13 cit.
7
Impact of Human Epidermal Growth Factor Receptor 2 in Patients With Metastatic Colorectal Cancer Treated With Chemotherapy Plus Bevacizumab or Anti-EGFRs: Exploratory Analysis of Eight Randomized Trials
Journal of Clinical Oncology|2025
11 cit.
8
247P Radiotherapy (RT), atezolizumab (atezo) and bevacizumab (bev) to increase organ preservation in rectal cancer: The TARZAN study
Annals of Oncology|2024
8 cit.
9
Molecular screening with liquid biopsy for anti-EGFR retreatment in metastatic colorectal cancer: preliminary data from the randomized phase 2 PARERE trial
Frontiers in Oncology|2024
7 cit.
10
Tumor Size Is Not Everything: Advancing Radiomics as a Precision Medicine Biomarker in Oncology Drug Development and Clinical Care. A Report of a Multidisciplinary Workshop Coordinated by the RECIST Working Group
JCO Precision Oncology|2024
6 cit.

Emerging Leaders

Drafting the new consensus

Researchers

1
Jennifer N. Durham
Sidney Kimmel Comprehensive Cancer Center
2
Bjarne R. Bartlett
State University of New York
3
Kellie N. Smith
Bloomberg (United States)
4
Hao Wang
University of Electronic Science and Technology of China
5
Lisa A. Gurski
National Comprehensive Cancer Network
6
Chiara Cremolini
University of Pisa
7
Deborah A. Freedman-Cass
Unknown
8
Fortunato Ciardiello
University of Campania "Luigi Vanvitelli"
9
Zhenqiang Sun
First Affiliated Hospital of Zhengzhou University
10
Zhen Zhang
Peking University Shenzhen Hospital

Papers

1
Rectal Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology
Journal of the National Comprehensive Cancer Network|2022
819 cit.
2
NCCN Guidelines® Insights: Bladder Cancer, Version 2.2022
Journal of the National Comprehensive Cancer Network|2022
302 cit.
3
Integrated analysis of single-cell and bulk RNA sequencing data reveals a pan-cancer stemness signature predicting immunotherapy response
Genome Medicine|2022
281 cit.
4
Upfront FOLFOXIRI plus bevacizumab with or without atezolizumab in the treatment of patients with metastatic colorectal cancer (AtezoTRIBE): a multicentre, open-label, randomised, controlled, phase 2 trial
The Lancet Oncology|2022
270 cit.
5
Bladder Cancer, Version 3.2024
Journal of the National Comprehensive Cancer Network|2024
236 cit.
6
NCCN Guidelines® Insights: Rectal Cancer, Version 3.2024
Journal of the National Comprehensive Cancer Network|2024
215 cit.
7
NCCN Guidelines® Insights: Kidney Cancer, Version 2.2024
Journal of the National Comprehensive Cancer Network|2024
166 cit.
8
Pan-cancer proteogenomics characterization of tumor immunity
Cell|2024
91 cit.
9
Upfront Modified Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan Plus Panitumumab Versus Fluorouracil, Leucovorin, and Oxaliplatin Plus Panitumumab for Patients With <i>RAS/BRAF</i> Wild-Type Metastatic Colorectal Cancer: The Phase III TRIPLETE Study by GONO
Journal of Clinical Oncology|2022
78 cit.
10
Lung tumor–infiltrating T<sub>reg</sub>have divergent transcriptional profiles and function linked to checkpoint blockade response
Science Immunology|2023
74 cit.

Current Senior Leaders

Wrote the book, still writing it

Researchers

1
Aimery de Gramont
Institut Hospitalier Franco Britannique
2
Pasi A. Jänne
Harvard University
3
Eric Van Cutsem
Universitair Ziekenhuis Leuven
4
Fairooz F. Kabbinavar
Kaiser Permanente
5
Sabine Tejpar
KU Leuven
6
Dirk Arnold
Asklepios Klinik Altona
7
Bert Vogelstein
Johns Hopkins University
8
Bruce E. Johnson
Harvard University
9
Matthew Meyerson
Broad Institute
10
Alberto Bardelli
IFOM

Papers

1
A technique for radiolabeling DNA restriction endonuclease fragments to high specific activity
Analytical Biochemistry|1983
25.2k cit.
2
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
New England Journal of Medicine|2004
11k cit.
3
<i>EGFR</i> Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
Science|2004
9.4k cit.
4
Genetic Alterations during Colorectal-Tumor Development
New England Journal of Medicine|1988
6.8k cit.
5
Surfing the p53 network
Nature|2000
6.6k cit.
6
The consensus molecular subtypes of colorectal cancer
Nature Medicine|2015
5.3k cit.
7
Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal Cancer
New England Journal of Medicine|2004
5k cit.
8
<i>MET</i> Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
Science|2007
4.5k cit.
9
The landscape of somatic copy-number alteration across human cancers
Nature|2010
4.1k cit.
10
Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
New England Journal of Medicine|2009
3.9k cit.

Reagents for Colorectal Cancer Treatments and Studies

Citation-validated products used in this field

🔥 Trending

Gaining adoption fast

⭐ Top Rated

Best all-around

Cell Signaling Technology

ZHX2 Antibody

Cited in 7 papers
#20937$317
View Evidence →
Cell Signaling TechnologyEvidence 65

PDGF Receptor beta Antibody Sampler Kit

Cited in 6 papers
#9970$581
View Evidence →
Cell Signaling TechnologyEvidence 66

FoxO1 (C29H4) Rabbit Monoclonal Antibody (PE Conjugate)

Cited in 6 papers
#14262$180,465
View Evidence →

🌟 All-Time

Most validated

RocheEvidence 75

VENTANA® anti-BRAF V600E (VE1) Mouse Monoclonal Primary Antibody

Cited in 31 papers
#760-5095 (also 08033706001)
View Evidence →
Thermo Fisher ScientificEvidence 77

Phospho-BRAF (Ser729) Polyclonal Antibody

Cited in 12 papers
#PA5-105501
View Evidence →
Cell Signaling TechnologyEvidence 66

VDAC Antibody

Cited in 7 papers
#4866$135,314
View Evidence →